KAP for Depression in Abstinent Opioid Users

Summary

The purpose of the study is to examine whether an investigational medication called ketamine along with psychotherapy is an effective treatment for depression in participants with a history of opioid addiction who have not abused opioids in at least 3 months. Participants will receive ketamine through intramuscular injection along with psychotherapy weekly for 8 weeks. Participation for eligible subjects who decide to enroll (including post-medication follow-up visits) will last about 16 weeks or 4 months.

Timeline

Start

2022-01-13

Primary completion

2023-03-20

Completion

2023-03-20

Outcome

Outcome not reported

Stopped: “Primary Investigator leaving institution”

Drugs

Indications